X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will be used to progress Microbiotica’s two lead oral Live Bacterial Therapeutics (LBTs), MB097 and MB310 to Phase 1b clinical studies. MB310 is a fully defined LBT comprising a consortium of bacteria for the treatment of Ulcerative Colitis (UC).
Lead Product(s): MB097
Therapeutic Area: Oncology Product Name: MB097
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Flerie Invest
Deal Size: $67.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 07, 2022
Details:
MB097 is a consortium of bacteria at the core of the microbiome signature predictive of patient response to Immune Checkpoint Inhibitor therapy. MB097 is in manufacturing process development for Ph1b study expected to start next year.
Lead Product(s): MB097
Therapeutic Area: Oncology Product Name: MB097
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
The collaboration is based on clinical studies conducted by CUH that evaluate immune checkpoint inhibitor drug response in cancer patients, combined with Microbiotica’s unrivalled microbiome profiling and analysis capability.
Lead Product(s): Live bacterial therapeutics,Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cancer Research UK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
